Welcome to our dedicated page for 60 degrees pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 degrees pharmaceuticals stock.
News about 60 Degrees Pharmaceuticals, Inc. (SXTP) centers on its work in vector-borne diseases and the commercial performance of its lead antimalarial product, ARAKODA ae (tafenoquine). Company announcements describe 60 Degrees Pharmaceuticals, Inc. as a pharmaceutical company focused on developing new medicines for vector-borne disease, with an FDA-approved product for malaria prophylaxis and multiple ongoing clinical programs.
Investors following SXTP news can read about updates on ARAKODA commercial activities, such as sales and marketing initiatives and pharmacy delivery trends, as well as information on clinical research in babesiosis. The company regularly reports milestones for its babesiosis trials, including the B-FREE Chronic Babesiosis Study, a Phase 2 open-label trial evaluating the ARAKODA regimen of tafenoquine over 90 days in patients with chronic babesiosis, and expanded access and randomized studies in hospitalized or high-risk patients with babesiosis.
News releases also highlight scientific collaborations and sponsored research, such as agreements with academic institutions to study tafenoquine against Babesia parasites and other pathogens associated with tick-borne illness. In addition, regulatory and corporate developments appear in the news flow, including disclosures about a reverse stock split intended to help maintain Nasdaq listing requirements and shareholder voting outcomes reported in SEC filings.
By reviewing the SXTP news feed, readers can track how 60 Degrees Pharmaceuticals, Inc. communicates progress on its malaria prophylaxis business, its vector-borne disease research pipeline, and key corporate actions affecting its Nasdaq-listed common stock and warrants. This page brings together these updates in one place for those monitoring the companys activities and public disclosures.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), a pharmaceutical company focused on vector-borne disease treatments, has announced an updated schedule for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation, and the management team will be available for one-on-one meetings during the conference. The presentation will be accessible via webcast for interested investors.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a company focused on developing medicines for vector-borne diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation on September 10 at 2:30 ET. Management will also conduct one-on-one meetings during the conference. The presentation will be available via webcast with replay access for approximately 90 days on the company's investor relations website.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has selected the Icahn School of Medicine at Mount Sinai as the central site for a Phase II clinical trial evaluating tafenoquine for chronic babesiosis treatment. The 90-day open-label study will assess the drug's efficacy in treating patients with disabling fatigue lasting at least six months.
The trial will evaluate ARAKODA® (tafenoquine) with a dosing regimen of 2 x 100 mg tablets administered orally for the first four days, followed by weekly doses for 12 weeks. The primary endpoint is fatigue resolution measured using a patient-reported outcome scale. Enrollment is expected to begin in Q4 2025 with completion targeted for Q2 2026.
This study is one of three clinical trials sponsored by 60 Degrees Pharma to evaluate tafenoquine for babesiosis, with data expected in H1 2026. The company plans to submit a New Drug Application (NDA) to the FDA in 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2025 financial results, highlighting a 19% year-over-year decline in net product revenues to $101,000 due to a temporary supply chain disruption. Despite lower revenues, the company achieved increased profitability with a gross profit of $51,000, up from $35,000 in Q2 2024.
Operating expenses decreased significantly to $1.86 million from $4.22 million in Q2 2024. The net loss improved to $1.84 million ($1.25 per share) compared to $4.29 million ($21.12 per share) in Q2 2024. With $1.97 million cash on hand and recent public offering proceeds of $4.46 million, the company projects runway through March 31, 2026.
Research studies indicate the total addressable U.S. market for ARAKODA for human babesiosis could reach $1.1 billion over the remaining 10-year patent life, with annual babesiosis incidence estimated between 25,000-380,000 cases.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has entered into a research agreement with Tulane University to study tafenoquine's effectiveness against Borrelia (Lyme disease) and Bartonella bacteria in cell culture. These pathogens, along with Babesia, are known as the "3Bs" commonly found in tick-borne illnesses.
The study aims to evaluate tafenoquine, an FDA-approved antimalarial drug marketed as ARAKODA®, for potential treatment of co-infections in babesiosis patients. Currently, tafenoquine is undergoing babesiosis trials at several sites. The drug's safety for malaria prophylaxis has been validated through six randomized, controlled trials lasting up to 12 months, though it remains unapproved for treating babesiosis, Borrelia, or Bartonella infections.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has closed its previously announced public offering, raising $5 million in immediate gross proceeds. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) with accompanying Series A-1 and A-2 warrants at $1.90 per share.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. If the Series A-2 warrants are fully exercised, the company could receive up to an additional $5 million in gross proceeds. H.C. Wainwright & Co. served as the exclusive placement agent, and the proceeds will be used for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has announced the pricing of a $5 million public offering with potential additional proceeds of up to $5 million through warrant exercises. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) at $1.90 per share, along with Series A-1 and A-2 warrants.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. H.C. Wainwright & Co. is serving as the exclusive placement agent, with closing expected around July 16, 2025. The company plans to use proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced the potential market size for ARAKODA® (tafenoquine) in treating human babesiosis, projecting maximum annual sales of $245 million and a cumulative market value of $1.1 billion through patent expiration in 2035.
The market assessment is based on comprehensive research including a 6,000-patient nationwide survey and feedback from 300 healthcare professionals. The company estimates a total addressable market of 380,000 patients annually.
Currently, three clinical trials are underway or planned to evaluate tafenoquine's safety and efficacy. The company expects to submit a New Drug Application (NDA) to the FDA in 2026, pending positive trial results.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced plans to submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. The submission will be supported by three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, including one company-sponsored study at North Carolina State University.
The studies demonstrated that tafenoquine was well-tolerated and effective in treating both experimental and naturally acquired Babesia infections in dogs. This development is significant as there are currently no FDA-approved oral treatments for canine babesiosis, an emerging tick-borne illness that affects hundreds to thousands of dogs annually in the United States.